The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity

Mov Disord. 2023 Jun;38(6):1105-1107. doi: 10.1002/mds.29385. Epub 2023 Mar 27.

Authors

Max Borsche^{1

2}, Neringa Pratuseviciute³, Susen Schaake¹, Frauke Hinrichs¹, Gabriel Morel³, Jan Uter^{1

2}, Katja Lohmann¹, Christine Klein¹, Dario R Alessi³, Johann Hagenah⁴, Esther Sammler^{3

5}

Affiliations

¹ Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
² Department of Neurology, University of Lübeck, Lübeck, Germany.
³ MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
⁴ Department of Neurology, Westküstenklinikum Heide, Heide, Germany.
⁵ Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom.

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / metabolism
Mutation / genetics
Parkinson Disease* / genetics
Phosphorylation

Substances

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
LRRK2 protein, human

Grants and funding